New drug shows promise in early cancer trial
NCT ID NCT02674152
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 27 times
Summary
This early-stage trial tested a new drug called BI 836880 in 29 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. The drug was given through an IV, and researchers monitored patients closely for any serious reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
INS Curie
Paris, 75248, France
-
Universitätsklinikum Augsburg
Augsburg, 86156, Germany
-
Universitätsklinikum Freiburg
Freiburg im Breisgau, 79106, Germany
Conditions
Explore the condition pages connected to this study.